Amgen Inc (BUE:AMGN)
ARS 10425 -25 (-0.24%) Market Cap: 153.50 Til Enterprise Value: 205.37 Til PE Ratio: 36.22 PB Ratio: 20.20 GF Score: 57/100

Amgen Inc and Adaptive Biotechnologies Corp Webinar on Targetting Covid-19 Transcript

Apr 09, 2020 / 03:00PM GMT
Release Date Price: ARS3765
Operator

(technical difficulty)

Aaron Gal
Sanford C. Bernstein & Co., LLC., Research Division - Senior Research Analyst

(technical difficulty) in real-time to figure out what you're asking and be able to ask those in the end of the prepared remark and the questions that we have set for this call. I also want to thank Arvind and the IR team at Amgen for setting up this call so quickly. I know we've already passed April 1, which probably created a bunch of havoc internally with the legal guys, and thank you for working through this and making this happen. So with that, I'm going to pass it over to David for some introductory remarks. David?

David M. Reese
Amgen Inc. - EVP of Research & Development

Thank you, Ronny, and thanks, everyone, for getting together. Good morning. As we all know, we're in the middle of an unprecedented crisis, the biggest public health challenge in the century. Certainly, the biggest public health challenge that any of us have seen in our lifetimes. And we felt, we being Adaptive and Amgen

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot